Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Cidofovir · 3 trials · 4 indications
| Name | Type | Description |
|---|---|---|
| Cidofovir | DRUG | - |
| Probenecid | DRUG | - |
Inclusion Criteria Concurrent Medication: Allowed: * Antiretroviral agents. * Oral trimethoprim/sulfamethoxazole. * Aerosolized pentamidine. * Dapsone. * Fluconazole. * Rifabutin. * Filgrastim (G-CSF). * p24 vaccine. Patients must have: * Diagnosis of AIDS by CDC criteria. * Diagnosis of periph...
Cidofovir is an investigational small molecule being studied for infectious disease indications including cytomegalovirus retinitis, HIV infections, and herpes simplex. It is developed by Gilead Sciences, Inc. (NASDAQ: GILD). The drug is currently in Phase 2 clinical development for these conditions.
Cidofovir is a small molecule antiviral agent. It works by inhibiting viral DNA polymerase, an enzyme essential for viral replication. This mechanism makes it active against DNA viruses including cytomegalovirus, herpes simplex virus, and other related pathogens.
Cidofovir is being developed by Gilead Sciences, Inc., a biopharmaceutical company traded on NASDAQ under the ticker symbol GILD. Gilead is conducting clinical trials to evaluate the drug's safety and efficacy in patients with viral infections.
Cidofovir is in Phase 2 clinical development. It has completed one Phase 2 trial, NCT00002437, which evaluated the drug for cytomegalovirus retinitis in patients with AIDS. The drug remains investigational and has not been approved by regulatory authorities.
Cidofovir has completed three clinical trials. NCT00002437 was a Phase 2 study in cytomegalovirus retinitis with 48 participants. NCT00002116 and NCT00002327 were Phase 1 studies in herpes simplex and venereal warts, respectively, with 30 and 40 participants. All trials are completed.
Yes, Cidofovir is also known as HPMPC, which stands for 1-(S)-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine dihydrate. This alternative name appears in clinical trial records, such as NCT00002116, which studied topical HPMPC for refractory mucocutaneous herpes simplex disease.